YOUR HEALTH FIRST
YOUR HEALTH FIRST
KINTHOMOL TAB
Methocarbamol Tablets USP
Composition : Each uncoated Tablet Contains :
Methocarbamol USP 500 mg.
Excipients q.s.
INDICATIONS:
Kinthomol Tablets USP is indicated as an adjunctive therapy for the relief of discomfort associated with acute painful musculoskeletal conditions.
Kinthomol Tablets USP is also indicated for control of muscle spasm in tetanus.
DOSAGE & ADMINISTRATION:
For Oral use:
Initial: 1.5 gm.(i.e. 3 Tablets) 4 times daily.
Maintenance: 1 gm. (2 Tablets) 4 times daily.
For the first time 48 to 72 hours, 6 gm / day is recommended (For severe conditions 8 gm. Daily may be administered). Thereafter reduce to approximately 4 gm. daily.
USAGE IN TETANUS:
Kinthomol does not replace the usual procedure of debridement tetanus antitoxin, penicillin, tracheotomy, attention to fluid balance and supportive care. Add Kinthomol injection to the regimen as soon as possible.
PHARMACOLOGY:
Kinthomol is a centrally acting skeletal muscle relaxant. Its mechanism of action has been established, but may be sue to general CNS depression. The drug has no direct action on the contractile mechanism of striated muscle, motor endplate or nerve fiber, it does not directly relax tense skeletal muscles.
Kinthomol is rapidly absorbed from the gastro intestinal tract following oral administration.
Kinthomol has an onset of action of 30 minutes.
Peak plasma levels occur approximately 2 hours after administration of 2 gm. The half-life is from 1 to 2 hours. Kinthomol is metabolized, probably in the liver and excreted in urine primarily as the glucuronide and sulphate conjugates of its metabolites.
A small amount is excreted in faeces.
ADVERSE REACTIONS :
Lightheadedness, dizziness, drowsiness, nausea, urticaria, rash conjunctivitis with nasal congestion, blurred vision, headache, fever.
PRECAUTIONS & WARNINGS:
a) Kinthomol may impair concentration; patients so affected should not drive or operate machinery.
b) Kinthomol is not recommended during pregnancy, especially during early pregnancy or in women who may become pregnant, unless potential benefits outweigh potential hazards.
c) It is not known whether Kinthomol is excreted in breast milk.
Exercise caution when administering to nursing women.
d) Safety and efficacy of Kinthomol in children below 12 years old has not been established, except in tetanus.
Learn More
OVERDOSAGE :
Overdosage often is conjunction with alcohol or other CNS depressants, is marked by coma and other signs of CNS depression.
TREATMENT OF OVERDOSE :
Treatment is essentially supportive. Simple isolated seizures may require only observation and supportive care. Repetitive seizures or status epilepticus require therapy. Diazepam i.v. is generally the agent of choice, parentral barbiturates have also been used.
CONTRAINDICATIONS
Kinthomol is contraindicated in hypersensitive patients, in coma or pre-coma states, brain, damage, myasthenia gravis or in patients with a history of epilepsy.
DRUG INTERACTIONS:
The CNS effects of Kinthomol may be potentiated by concomitant administration of other CNS depressants such as alcohol.Kinthomol has also been stated to potentiate the effects of anorectics, antimuscarinics and some psychotropic agents.Kinthomol may cause color interference in certain screening tests for 5 hydroxy indole acetic acid (5-HIAA) and vanillylmandelic acid (VMA)
.STORAGE CONDITIONS:
Keep in a cool, dry place, below 25ºC. Protect from light.
PRESENTATION :
Kinthomol Tablets USP: A strip of 10 tablets. in Mono Pack.
NAFDAC Reg. No. : B4-5365
Manufactured by:
Brussels Laboratories Pvt. Ltd.33, Changodar Ind. Estate, Changodar-382 210.Dist. Ahmedabad (Gujarat, India)
Marketed by
KINGZY PHARMACEUTICALS LTD.
142 Okporo Road, Port Harcourt,
Rivers State, NIGERIA
Mfg. Lic. No. : G/1369
Our Partners
